Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting.
Takuya ShoGoki SudaKoji OgawaMegumi KimuraTomoe ShimazakiOsamu MaeharaTaku ShigesawaKazuharu SuzukiAkihisa NakamuraMasatsugu OharaMachiko UmemuraNaoki KawagishiMitsuteru NatsuizakaMasato NakaiKenichi MorikawaKen FuruyaMasaru BabaYoshiya YamamotoTomoe KobayashiTakashi MeguroAkiyoshi SagaTakuto MiyagishimaHideki YokooToshiya KamiyamaAkinobu TaketomiNaoya SakamotoPublished in: JGH open : an open access journal of gastroenterology and hepatology (2019)
Lenvatinib showed high early response rate and tolerability in patients with advanced HCC. Favorable outcomes were similarly observed in patients who did not meet the REFLECT inclusion criteria.